title: Neuroimaging of therapy-associated brain tissue abnormalities.
abstract: OBJECTIVE
  This study summarizes recent advances in neuroimaging of therapy-related brain tissue abnormalities.
  
  
  RESULTS
  Pseudoprogression constitutes a typical posttherapeutic phenomenon in patients with glioblastoma treated with radiochemotherapy with temozolomide. Advanced MRI techniques, such as diffusion MRI and perfusion MRI, can be helpful to distinguish it from true tumor progression. In clinical trials on amyloid-modifying therapies in Alzheimer's disease patients, previously unknown, characteristic nonhemorrhagic and hemorrhagic amyloid-related imaging abnormalities have been observed. Awareness of this phenomenon is essential for therapy monitoring. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome can both occur as a complication of a variety of systemic drug therapies and present with a wide spectrum of clinical and imaging findings. The pathomechanisms underlying these different therapy-related brain tissue changes are only poorly understood.
  
  
  CONCLUSIONS
  Neuroimaging, including advanced MRI techniques, plays a key role in the identification and monitoring of therapy-associated brain tissue abnormalities. However, future imaging studies should focus on the pathomechanism underlying these phenomena.
authors.affiliation: Department of Neuroradiology, University Hospital Munich, Munich, Germany.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Linn
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D001927:Brain Diseases / Q000175:diagnosis* / Q000209:etiology*; D059248:Chemoradiotherapy / Q000009:adverse effects; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D059906:Neuroimaging; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide